JUMP REPORT
NOVAVAX (NVAX)
EARNINGS RELEASE - AUGUST 10 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.42/share REV: 39.58/M
___________________________________________________________
LAST QTR: EPS: -.70/share ACTUAL: -.58/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 1.35/share REV: 234.3/M
____________________________________________________________
FULL YR: EPS: 7.97/share REV: 1,100/M
____________________________________________________________
BEAT/MISS RECORD: 35% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 83.4, -12.9, 7.77
EXPECTED JUMP MOVE THIS QUARTER: 15-20%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before tradin
Links To Latest News and Headlines
Yahoo Finance health care correspondent Anjalee Khemlani joins the Live show to discuss Florida being the only state not to order Pfizer and Moderna’s FDA approved COVID vaccines for children 5-years old and under.
Yahoo Finance Live’s Brian Sozzi reports that the FDA has authorized Moderna and Pfizer COVID vaccines for children under the age of 5.
Dr. Paul Offit, Children’s Hospital of Philadelphia Vaccine Education Center Director and Professor of Pediatrics, explains the importance of FDA recommending COVID vaccines for children from Pfizer and Moderna and the symptoms parents should expect in vaccinated kids.
Is Novavax stock a buy or sell after the FDA’s advisors endorsed the company’s Covid shot? Is NVAX stock a buy or sell right now?
Shares of Novavax (NASDAQ: NVAX) had declined by nearly 11% as of 10:56 a.m. ET on Thursday amid the Nasdaq’s broader decline of more than 3.8%. Its shares are likely falling due to the Federal Reserve’s decision yesterday to hike interest rates, which disproportionately hurts growth stocks like Novavax. Plus, the Food and Drug Administration’s (FDA) nonbinding advisory committee also ruled yesterday that the coronavirus shots made by Moderna and Pfizer are likely to be safe and effective for infants, and both are major Novavax competitors in the vaccine market.
StockJumpers analysis and trade plans are finalized and uploaded generally one house before market cloase (3PM EST) for most events unless noticed.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
Members who are too busy to manual trade can use Trade Assist. For more information visit here
| Avg Daily Volume: 8,831,772 Market Cap: 5.65B Sector: Healthcare Short Interest: 13.87 |
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.
by Team Stockjumpers